| Objective To evaluate the control effect of Rouganjian on liver fibrosis in rats, and the change of TGF-β1and Smads in liver of. To explore the mechanism of Rouganjian Decoction on liver fibrosis.Methods105male SD rats with200g±20g in weight were randomly divided into blank control group, model control group, colchicines group, fuzhenghuayu group, high dosage group,middle doseage group and low dosage group of rouganjian,15in every group. Using the CCL4composite approach to make the rat modle. The course of treat-ment was12weeks.After treatment,All the rats was killed,and the materials and blood was taken,and to detect AST, ALT, PH,TP, HA, LN, C-Ⅳ, PC Ⅲ after eight weeks. Investigating the variation of liver histology, Hestain and Masson trichrome stain. Meanwhile detecting TGF-β1and protein expression of Smad3, Smad7by immune-histochemical method.Result The general condition of rats in all treatment groups are worse than the blank group, but better than the model group, and there was no significant difference between Rouganjian high, medium, low dose group. The normal group without hepatic fibrosis, and the rats in the model group were all occurred in liver fibrosis, and liver fibrosis is the most serious. There is no significant difference between hepatic fibrosis degree and the quantity of the remaining5group, P>0.05. Compared with the normal group, the serum concentrations of AST, ALT and PH increased significantly, while TP changes little; but compared with the model group, the treatment group significantly reduced serum liver function, P<0.01, the difference between change and is not significant, P>0.05. Liver fibrosis indexes, each index all increased compared with control group, the treatment group was lower than that of model group, P<0.01, there was no significant difference between Rouganjian Decoction high, medium, low dose group and colchicine group, Fuzheng Huayu capsule group, P>0.05. In normal rat liver tissue of TGF-β1 and Smad3were significantly lower in model group and each treatment group, and there were significant differences, P<0.01or P<0.05; and the content of liver tissue in model rats of TGF-β1and Smad3, Smad7in the group the highest, difference signi-ficantly, with statistical significance, P<0.05.Each treatment groups, and no significant difference in expression of the two, P>0.05; there was no significant difference of Smad7in normal group and model group in the content, P>0.05.While the normal group and model group and all treatment groups significantly, P<0.01; but there is no comparison between the treatment group was signi-ficant difference, P>0.05.Conclusion1.Rouganjian can effectively improve liver fibrosis rats induced by CC14liver function (ALT, AST, PH, TP), and can decrease the level of serum in experimental hepatic fibrosis rat hepatic fibrosis and four indexes (HA, LN, Ⅳ-C, PC Ⅲ).2.Patho-logical changes of hepatic tissue Rouganjian decoction can ef-fectively improve liver fibrosis rats induced by CC14reduction of, fibrous tissue hyperplasia.3.Rouganjian decoction can reduce the expression of TGF-β1in liver tissue of hepatic fibrosis rats induced by CC14in. This may be one of the mechanisms of Rouganjian Decoction in prevention and treatment of liver fibrosis.4.Even though both increased expression and Smad7Smad3expression, is still unable to determine Rouganjian Decoction for the intervention of liver TGF-β1/Smad3signal transduction pathway in liver fibrosis.5.No significant difference of efficacy between Rouganjian Decoction dose groups. |
PDF Full Text Request